Palo Alto – June 4, 2019 – Cooley advised Goldfinch Bio on its strategic collaboration with Gilead Sciences to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases. Partner Lila Hope led the Cooley team advising Goldfinch.
Under the collaboration, Gilead has exclusive options to license worldwide rights to certain products directed toward targets emerging from Goldfinch’s proprietary Kidney Genome Atlas (KGA), a comprehensive registry of patients with kidney diseases that integrates genomic, transcriptomic and proteomic data with patient clinical profiles.
“We are excited to partner with Gilead Sciences, a biopharmaceutical company known for its science-driven innovation and productivity,” Tony Johnson, president and CEO of Goldfinch, said in a news release. “There is significant unmet need to improve health outcomes for patients with kidney diseases. This partnership will leverage Goldfinch’s KGA platform to identify new therapeutic targets and Gilead’s proven track record of efficiently advancing life-saving therapies for patients.”
Goldfinch will receive $55 million in upfront payments and an additional $54 million to support the development of the KGA platform for DKD. Further, Goldfinch is eligible to receive up to $1.95 billion in potential payments for the first five collaboration programs based on the successful achievement of research, development, regulatory and commercial milestones, and tiered royalties on sales of potential products stemming from the collaboration.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,000+ lawyers across 15 offices in the United States, Asia and Europe.